Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

From Molecule through Market… the vision is clear — to be successful pharmaceutical companies and their valued development partners need to understand the underlying challenges, trends, and opportunities that each molecule, compound, diagnostic, or biotech product faces as it progresses along the development continuum. Staying true to our vision that no sector can stand alone and succeed in an ever-increasingly complex market, PharmaVOICE has once again brought together dozens of industry executives to raise their VOICE on what they see happening in every phase of development and beyond. We thank them for providing their insights and predictions on what’s happening in early development through postlaunch, and how the new Pharma 3.0 model will impact all areas of the pipeline and market. As always, we are offering exclusive bonus editorial in our online edition. The content found online is more than just a mirror of the print version; it truly includes additional valuable insights and commentary. Analysts at Booz & Company believe in the coming year pharmaceutical leaders will be focused on developing and stitching together a complex array of capabilities. Certain capabilities, including major outsourcing arrangements, matrixed organizational models, and collaborative partnerships with stakeholders, point to the need to effectively manage a networked enterprise. Success in this area depends on putting in place the right combination of formal and informal mechanisms that define and influence networked organizations. Our experts agree, and furthermore predict the rise of superconsumers, who will be better informed because of technology-enabled processes and benefit from the shift in concentration from products to patients. Booz analysts add that in the future, winning pharmaceutical companies will be capable pharmaceutical companies, which have identified clear decision-making, organization design, compensation systems, compliance, and business planning as important formal mechanisms for enabling accountability for results. Booz & Company’s 2012 Healthcare (Pharma) Industry Perspective reveals the latest thinking on key insights, trends, and the forecast for the year ahead that fall into four critical and rapidly changing aspects of the industry-research, commercial operations, supply chains, and networking. While the industry faces serious problems, companies can survive and thrive if they adopt highly differentiated strategies. In addition to building capable R&D?engines, a capable supply chain, and a networked enterprise, going forward, four trends will require not just more significant cuts in traditional resources, but a focus on building distinctive new capabilities. First, cost containment will continue to create a more restrictive market access environment with greater pricing pressures, additional reimbursement restrictions, and new or altered drug procurement systems. Next, new product launches will increasingly be focused on high-value specialty indications. Third, trade liberalization will open new opportunities in distribution and trade channels. Finally, emerging markets, which have very different healthcare models for marketing authorization, pricing, reimbursement, and distribution, are forecast to make up 30% of the global pharmaceutical market by 2015, compared with 19% in 2010. For more information, visit booz.com. Their Word… Denise Myshko Managing Editor Phase II is becoming a critical stage for ­planning the potential launch and marketing of products. Robin Robinson Senior Editor Pharmacovigilance is increasingly critical and progressively more ­difficult to pin down in today’s environment. Kim Ribbink Features Editor The U.K. government has taken forward-thinking steps to ­encourage the research and ­development of products and to bring them to the market in a country that has long been a leader in innovation. Carolyn Gretton Contributing Editor As part of a continued drive to cut costs, pharma companies are increasingly ­outsourcing industry-specific functions such as discovery and development. Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh Managing EDitor Denise Myshko Senior EDitor Robin Robinson features EDitor Kim Ribbink Contributing Editor Carolyn Gretton design associate Ariel Medel national account managerS Trish Kane Cathy Tracy WEBCAST?NETWORK?PRODUCER Daniel Limbach CIRCULATION Assistant Kathy Deiuliis Copyright 2012 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Twelve, Number Three PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O.?Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices. Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. PharmaVoice Coverage and Distribution: Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O.?Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197. Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com. Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com. Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change. Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O.?Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com. Volume 12 • Number 3 Letters Send your letters to feedback@pharma­voice.com. Please include your name, title, company, and business phone number. Letters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC. Coming in April 2012 > Competitive Intelligence > Patient Communities > Clinical Trial Technologies > C-Suite: Digital/Interactive Agencies > GlobaI Patient Recruitment > Market Report: France > Showcase Features — Medical Affairs and IRBs

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK